09.05.2024 13:48:49
|
Merck' Keytruda Receives Approval From Health Canada For Biliary Tract Carcinoma In Adults
(RTTNews) - Thursday, Merck & Co., Inc. (MRK) announced that Health Canada has approved Keytruda, also known as pembrolizumab, for the treatment of adult patients with locally advanced unresectable or metastatic biliary tract carcinoma when used alongside gemcitabine-based chemotherapy.
Biliary tract carcinoma is a rare and aggressive group of cancers affecting the gallbladder and bile ducts.
The company said that the approval is based on the findings of the Phase 3 KEYNOTE-966 trial, showing a significant improvement in overall survival compared to chemotherapy alone.
Keytruda was initially sanctioned in Canada in 2015 and is now prescribed for various conditions such as advanced renal cell carcinoma, bladder cancer, non-small cell lung carcinoma, primary mediastinal B-cell lymphoma, classical Hodgkin lymphoma, colorectal cancer, endometrial carcinoma, cervical cancer, esophageal cancer, triple-negative breast cancer, melanoma, and head and neck squamous cell carcinoma.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Merck Co.mehr Nachrichten
18:02 |
Zuversicht in New York: Dow Jones mit Kursplus (finanzen.at) | |
10.12.24 |
Angespannte Stimmung in New York: Dow Jones zum Ende des Dienstagshandels in Rot (finanzen.at) | |
10.12.24 |
Handel in New York: Dow Jones verbucht Verluste (finanzen.at) | |
10.12.24 |
Zuversicht in New York: Dow Jones zeigt sich am Dienstagmittag fester (finanzen.at) | |
10.12.24 |
Dow Jones 30 Industrial-Wert Merck-Aktie: So viel Gewinn hätte ein Merck-Investment von vor 5 Jahren eingefahren (finanzen.at) | |
10.12.24 |
Minuszeichen in New York: Dow Jones zum Handelsstart schwächer (finanzen.at) | |
09.12.24 |
Pluszeichen in New York: Dow Jones am Montagmittag mit grünem Vorzeichen (finanzen.at) | |
05.12.24 |
Börse New York: Dow Jones sackt schlussendlich ab (finanzen.at) |